期刊文献+

普拉曲沙的合成工艺优化 被引量:1

Improved Synthetic Process of Pralatrexate
原文传递
导出
摘要 本研究改进了普拉曲沙(1)的合成工艺。4-甲氧甲酰基苯乙酸甲酯(2)与3-溴丙炔反应得到α-丙炔基-α-(4-甲氧甲酰基苯基)乙酸甲酯(3),反应中使用六甲基二硅基氨基锂(LiHMDS)代替六甲基二硅基氨基钾(KHMDS),反应选择性提高,生成的3与杂质4-[(4-甲氧基羰基)-1,6-庚二炔-4-基]苯甲酸甲酯(8)的比例由3∶1提高至99∶1。3与6-溴甲基-2,4-二氨基蝶啶(4)发生亲电取代反应,再经水解、脱羧和缩合反应得到N-[4-[1-[(2,4-二氨基-6-蝶啶基)-甲基]-3-丁炔-1-基]苯甲酰基]-L-谷氨酸二甲酯(7),最后经酯水解、酸化反应生成目标产物1。合成1时,通过分批加氢氧化钠溶液的方式,将过度水解杂质的含量控制在0.1%以下,随后直接酸化,避免因使用醇溶剂导致消旋化的发生。该工艺所得产品1纯度99.85%,ee 99.74%,总收率由27%提高至43%。 The synthetic process of pralatrexate(1)was improved.Methyl 4-(2-methoxy-2-oxoethyl)-benzoate(2)reacted with 3-bromoprop-1-yne to giveα-propynyl-α-(4-methoxyformylphenyl)methyl acetate(3).Using lithium bis(trimethylsilyl)amide(LiHMDS)instead of potassium bis(trimethylsilyl)amide(KHMDS),the reaction selectivity increased,and the ratio of compound 3 to methyl 4-[4-(methoxycarbonyl)hepta-1,6-diyn-4-yl]benzoate(8)was increased from 3∶1 to 99∶1.Compound 3 reacted with 6-(bromomethyl)pteridine-2,4-diamine(4)by electrophilic substitution,then followed by hydrolysis,decarboxylation and condensation reaction to obtain dimethyl N-[4-[1-(2,4-diaminopteridin-6-yl)but-3-yn-1-yl]benzoyl]-L-glutamate(7),and the target compound 1 was prepared by ester hydrolysis and acidification.In this reaction,the content of excessively hydrolyzed impurity controlled was less than 0.1%by adding sodium hydroxide solution in batches,and then direct acidification could avoid racemization caused by the use of alcohol solvents.The purity of the product 1 obtained by this process was 99.85%with the ee value of 99.74%,and the total yield was increased from 27%to 43%.
作者 陈成富 文浩 李燕 张乃华 张贵民 CHEN Chengfu;WEN Hao;LI Yan;ZHANG Naihua;ZHANG Guimin(Shandong Newtime Pharmaceutical Co.,Ltd.,Linyi 273400;International Pharmaceutical Engineering Lab.of Shandong Province,Linyi 273400)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2020年第8期982-986,共5页 Chinese Journal of Pharmaceuticals
关键词 普拉曲沙 工艺改进 反应选择性 pralatrexate process improvement reaction selectivity
  • 相关文献

参考文献1

二级参考文献13

  • 1RILEY K. FDA approves first drug for treatment of peripheral T- cell lymphoma [ J ]. Mul Cell Pharmacol,2009,1 (4) : 230 - 232.
  • 2FOLOTYN [ EB/OL ]. [ 2010 - 05 ]. http ://www. folotyn. com/ sites/default/files/pdf/Folotyn_PI. pdf.
  • 3IZBICKA E,DIAZ A,STREEPER R, et al. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers [ J ]. Cancer Che- mother Pharmacol,2009,64 ( 5 ) :993 - 999.
  • 4MARNEROS AG, GROSSMAN ME, SILVERS DN,et al. Prala-trexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin ero- sions[ J ]. Blood ,2009,113 (25) :6338 - 6341.
  • 5LEITENBERGER JJ, BERTHELOT CN, POLDER KD, et al. CD4^+ CD56^+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate [ J ]. J Am Acad Dermatol, 2008,58 ( 3 ) : 480 - 484.
  • 6DAMAJ B. In vitro and in vivo effects of pralatrexate (PDX) on the survival and growth of the A549 non-small cell lung cancer cell line. [ EB/OL]. [ 2008 -04 - 12 ]. http ://www. aaermeet- ing abstracts. org/cgi/content/meeting_abstract/200S/I _Annual_ Meeting/2298.
  • 7MARCHI E,PAOLUZZI L,SCOTTO L,et al. Pralatrexate is syn- ergistic with the proteasome inhibitor Bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies [ J ]. Clin Cancer Res ,2010,16( 14 ) :3648 - 3658.
  • 8TONER LE, VRHOVAC R, SMITH EA, et al. The schedule-de- pendent effects of the novel antifolate pralatrexate and gemcit- abine are superior to methotrexate and cytarabine in models of hu- man Non-Hodgkin's lymphoma [ J ]. Clin Cancer Res, 2006, 12 (3) :924 -932.
  • 9KRUG LM,HEELAN RT,KRIS MG. Phase II trial of pralatrexate (10-propargyl-10-deaz- aamino pterin, PDX) in patients with unresectable malignant pleural mesothelioma[ J ]. J Thorac Oncol , 2007,2(4) :317 - 320.
  • 10AZZOLI CG,KRUG L,MILLER V, et al. Phase I study of the antifolate pralatrexate given with vitamin B12 and folic acid sup- plementation in patients ( pts ) with advanced non-small cell lung cancer (NSCLC) [ J]. J Clin Oncol, 2007,25 (18S) : 13006.

共引文献4

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部